{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:52:21Z","timestamp":1791535941514,"version":"4.3.4"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic sclerosis (SSc) belongs to the group of connective tissue diseases and is associated with the occurrence of disease-specific autoantibodies. Although it is still controversial whether these antibodies contribute to pathogenesis, there are new insights into the development of these specific antibodies and their possible pathophysiological properties. Interestingly, they are associated with specific clinical manifestations, but for some rarer antibodies this association is not fully clarified. The aim of this study is a comprehensive analysis of the serum autoantibody status in patients with SSc followed by correlation analyses of autoantibodies with the clinical course of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Serum from SSc patients was analyzed using a line blot (EUROLINE, EUROIMMUN AG) for SSc-related autoantibodies. Autoantibodies to centromere, Topo-1, antimitochondrial antibodies (AMA) M2 subunit, angiotensin II type 1 receptors (AT\n                      <jats:sub>1<\/jats:sub>\n                      R) and endothelin-1 type-A-receptors (ET\n                      <jats:sub>A<\/jats:sub>\n                      R) were also determined by ELISA. We formed immunological clusters and used principal components analysis (PCA) to assign specific clinical characteristics to these clusters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 372 SSc patients were included. 95.3% of the patients were antinuclear antibody positive and in 333 patients at least one SSc specific antibody could be detected. Four immunological clusters could be found by PCA. Centromere, Topo-1 and RP3 all formed own clusters, which are associated with distinct clinical phenotypes. We found that patients with an inverted phenotype, such as limited cutaneous SSc patients within the Topo-1 cluster show an increased risk for interstital lung disease compared to ACA positive patients. Anti-AT\n                      <jats:sub>1<\/jats:sub>\n                      R and anti-ET\n                      <jats:sub>A<\/jats:sub>\n                      R autoantibodies were measured in 176 SSc patients; no association with SSc disease manifestation was found. SSc patients with AMA-M2 antibodies showed an increased risk of cardiovascular events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our in large cluster analysis, which included an extended autoantibody profile, we were able to show that serologic status of SSc patients provides important clues to disease manifestation, co-morbidities and complications. Line blot was a reliable technique to detect autoantibodies in SSc and detected rarer autoantibodies in 42% of our patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.1045523","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T12:14:42Z","timestamp":1672834482000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Comprehensive autoantibody profiles in systemic sclerosis: Clinical cluster analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jakob","family":"H\u00f6ppner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Tabeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Casteleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Windisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R\u00fcdiger","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f6rte","family":"Huscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.587773","article-title":"Classical disease-specific autoantibodies in systemic sclerosis: Clinical features, gene susceptibility, and disease stratification","volume":"7","author":"Yang","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1906593116","article-title":"HLA and autoantibodies define scleroderma subtypes and risk in African and European americans and suggest a role for molecular mimicry","volume":"117","author":"Gourh","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.930970","article-title":"Can antinuclear antibodies have a pathogenic role in systemic sclerosis","volume":"13","author":"Chepy","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-immunol-032414-112205","article-title":"Autoantigens as partners in initiation and propagation of autoimmune rheumatic diseases","volume":"34","author":"Rosen","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.925741","article-title":"Pathogenetic aspects of systemic sclerosis: A view through the prism of b cells","volume":"13","author":"Melissaropoulos","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200311000-00016","article-title":"Autoimmunity in scleroderma: The origin, pathogenetic role, and clinical significance of autoantibodies","volume":"15","author":"Harris","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/2397198319870667","article-title":"Pathogenic roles of autoantibodies in systemic sclerosis: Current understandings in pathogenesis","volume":"5","author":"Sen\u00e9cal","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"B13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg170","article-title":"The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis","volume":"42","author":"Hesselstrand","year":"2003","journal-title":"Rheumatology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000904","article-title":"Scleroderma autoantibodies in guiding monitoring and treatment decisions","volume":"34","author":"Shah","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000250","article-title":"Mechanistic and clinical insights at the scleroderma-cancer interface","volume":"2","author":"Shah","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.40893","article-title":"Protective effect against cancer of antibodies to the Large subunits of both RNA polymerases I and III in scleroderma","volume":"71","author":"Shah","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac188","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort","author":"Zanatta","year":"2022","journal-title":"Rheumatol (Oxf)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rheumatology\/keac287","article-title":"Anti-topoisomerase-positive limited systemic sclerosis has a propensity for interstitial lung disease but is linked to favorable prognosis","author":"Desai","year":"2022","journal-title":"Rheumatol (Oxf)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12051067","article-title":"Autoantibodies versus skin fibrosis extent in systemic sclerosis: A case-control study of inverted phenotypes","volume":"12","author":"Tieu","year":"2022","journal-title":"Diagnostics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (Scleroderma) cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-015-0505-4","article-title":"Functional autoantibodies in systemic sclerosis pathogenesis","volume":"17","author":"Kill","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"B23","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/ar4457","article-title":"Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis","volume":"16","author":"Kill","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.786039","article-title":"Functionally active antibodies to the angiotensin II type 1-receptor measured by a luminometric bioassay do not correlate with clinical manifestations in systemic sclerosis: A comparison with antibodies to vascular receptors and topoisomerase I detected b","volume":"12","author":"Bankamp","year":"2021","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3639-4","article-title":"Anti-angiotensin II type 1 receptor autoantibodies (AT1R-AAs) in patients with systemic sclerosis: lack of association with disease manifestations","volume":"37","author":"\u0130lgen","year":"2017","journal-title":"Rheumatol Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.075002","article-title":"Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis","volume":"55","author":"Rigamonti","year":"2006","journal-title":"Gut"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.01.014","article-title":"Is prevalence of PBC underestimated in patients with systemic sclerosis","volume":"41","author":"Norman","year":"2009","journal-title":"Dig Liver Dis"},{"key":"B31","first-page":"68","article-title":"Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis","volume":"58","author":"Gupta","year":"1984","journal-title":"Clin Exp Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)62059-X","article-title":"The anticentromere antibody: Disease specificity and clinical significance","volume":"59","author":"Powell","year":"1984","journal-title":"Mayo Clin Proc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.41.6.612","article-title":"Anticentromere antibody in primary biliary cirrhosis","volume":"41","author":"Bernstein","year":"1982","journal-title":"Ann Rheum Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00501.2009","article-title":"Impaired cardiovascular function in primary biliary cirrhosis","volume":"298","author":"Jones","year":"2022","journal-title":"Am J Physiol - Gastrointest Liver Physiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12452","article-title":"Coronary artery disease in primary biliary cirrhosis: A systematic review and meta-analysis of observational studies","volume":"45","author":"Ungprasert","year":"2015","journal-title":"Hepatol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000493","article-title":"Risk of cerebrovascular accident in patients with primary biliary cirrhosis: A systematic review","volume":"28","author":"Ungprasert","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4254\/wjh.v3.i4.93","article-title":"Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease","volume":"3","author":"Doycheva","year":"2011","journal-title":"World J Hepatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2010.00717.x","article-title":"Primary biliary cirrhosis is associated with oxidative stress and endothelial dysfunction but not increased cardiovascular risk","volume":"40","author":"Cash","year":"2022","journal-title":"Hepatol Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/art.11113","article-title":"Evidence-based guidelines for the use of immunologic tests: Anticentromere, scl-70, and nucleolar antibodies","volume":"49","author":"Reveille","year":"2003","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"Classification criteria for systemic sclerosis: An American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2022.100141","article-title":"Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application","volume":"5","author":"Damoiseaux","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2021.1907842","article-title":"Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests","volume":"54","author":"Alkema","year":"2021","journal-title":"Autoimmunity"},{"key":"B43","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.895501","article-title":"Endothelin b receptor immunodynamics in pulmonary arterial hypertension","volume":"13","author":"Tabeling","year":"2022","journal-title":"Front Immunol"},{"key":"B45","volume-title":"jamovi. (Version 2.3) [Computer Software]","year":"2022"},{"key":"B46","volume-title":"R: A language and enviroment for statistical computing","author":"Tream","year":"2021"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v025.i01","article-title":"FactoMineR: An r package for multivariate analysis","volume":"25","author":"L\u00ea","year":"2008","journal-title":"J Stat Soft"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202849","article-title":"The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis","volume":"73","author":"Cottrell","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"R172","DOI":"10.1186\/ar3495","article-title":"Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: Correlation with characteristic clinical features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1046\/j.0022-202X.2003.22121.x","article-title":"Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma","volume":"122","author":"Yamamoto","year":"2004","journal-title":"J Invest Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.03.001","article-title":"Autoantibodies to intracellular antigens: Generation and pathogenetic role","volume":"10","author":"Racanelli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072136","article-title":"Neutrophil extracellular traps generation relates with early stage and vascular complications in systemic sclerosis","volume":"9","author":"Didier","year":"2020","journal-title":"J Clin Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/SMJ.0b013e31815838ce","article-title":"Systemic sclerosis and malignancy: A review of the literature","volume":"101","author":"Wooten","year":"2008","journal-title":"South Med J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.111906","article-title":"Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: Analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls","volume":"69","author":"Arnett","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2001.20268","article-title":"Systemic sclerosis in 3 US ethnic groups: A comparison of clinical, sociodemographic, serologic, and immunogenetic determinants","volume":"30","author":"Reveille","year":"2001","journal-title":"Semin Arthritis Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/anr.1780320109","article-title":"Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma","volume":"32","author":"McNeilage","year":"1989","journal-title":"Arthritis Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/art.10760","article-title":"A comparison between anti-TH\/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement","volume":"48","author":"Mitri","year":"2003","journal-title":"Arthritis Rheumatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1,012 Italian patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.1780370111","article-title":"Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"37","author":"Kuwana","year":"1994","journal-title":"Arthritis Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/ar628","article-title":"The clinical relevance of autoantibodies in scleroderma","volume":"5","author":"Ho","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken488","article-title":"Risk factors for death and the 3-year survival of patients with systemic sclerosis: The French Itin\u00e9rAIR-scl\u00e9rodermie study","volume":"48","author":"Hachulla","year":"2009","journal-title":"Rheumatology"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac047","article-title":"Autoantibody profiles associated with morbidity and mortality in scleroderma renal crisis","volume":"61","author":"Tsuji","year":"2022","journal-title":"Rheumatol (Oxf)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310409","article-title":"Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma)","volume":"31","author":"Reimer","year":"1988","journal-title":"Arthritis Rheumatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep215","article-title":"A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis","volume":"48","author":"Nihtyanova","year":"2009","journal-title":"Rheumatol (Oxf)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000167","article-title":"Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease","volume":"20","author":"Bhavsar","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: A cross-sectional analysis of data from an Australian cohort","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2011.01688.x","article-title":"South Australian scleroderma register: Autoantibodies as predictive biomarkers of phenotype and outcome","volume":"15","author":"Graf","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes055","article-title":"Evaluation of a new multi-parallel line immunoassay for systemic sclerosis-associated antibodies in an Asian population","volume":"51","author":"Low","year":"2012","journal-title":"Rheumatol (United Kingdom)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.2.121","article-title":"Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis","volume":"61","author":"Dick","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew298","article-title":"Survival and organ involvement in patients with limited cutaneous systemic sclerosis and antitopoisomerase-I antibodies: Determined by skin subtype or auto-antibody subtype? a long-term follow-up study","volume":"55","author":"Kranenburg","year":"2016","journal-title":"Rheumatol (United Kingdom)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rap\/rky002","article-title":"Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis","volume":"2","author":"Caetano","year":"2018","journal-title":"Rheumatol Adv Pract"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac287","article-title":"Anti-topoisomerase-positive limited systemic sclerosis has a propensity for interstitial lung disease but is linked to favourable prognosis","volume":"2022","author":"Desai","year":"2022","journal-title":"Rheumatology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/art.41668","article-title":"Tocilizumab prevents progression of early systemic sclerosis associated interstitial lung disease","volume":"73","author":"Roofeh","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03009742.2021.1887927","article-title":"Anti-Ro52\/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients","author":"Lee","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"R50","DOI":"10.1186\/ar3763","article-title":"Clinical significance of antibodies to Ro52\/TRIM21 in systemic sclerosis","volume":"14","author":"Hudson","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199211000-00001","article-title":"The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-scl","volume":"71","author":"Marguerie","year":"1992","journal-title":"Med (United States)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/art.38428","article-title":"Clinical and serologic correlates of anti-pm\/scl antibodies in systemic sclerosis: A multicenter study of 763 patients","volume":"66","author":"D\u2019Aoust","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.6.683","article-title":"Antibodies to Th\/To ribonucleoprotein in patients with localized scleroderma","volume":"40","author":"Yamane","year":"2001","journal-title":"Rheumatology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01991.x","article-title":"Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations","volume":"130","author":"van Eenennaam","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/art.42152","article-title":"Over one-third of Th\/To antibody positive scleroderma patients develop pulmonary hypertension in long-term follow-up","volume":"74","author":"Suresh","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/r6fqel","article-title":"Anti-NOR90 antibody associated with paraneoplastic systemic sclerosis","volume":"40","author":"Duffau","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B86","article-title":"Autoantibodies to NOR 90\/hUBF: Longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response","volume":"29","author":"Dagher","year":"2002","journal-title":"J Rheumatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab575","article-title":"Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia","volume":"61","author":"Yamashita","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B88","article-title":"Anti-Ku antibodies in connective tissue diseases: Clinical and serological evaluation of 14 patients","volume":"29","author":"Franceschini","year":"2002","journal-title":"J Rheumatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073981","article-title":"Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: A European EUSTAR-initiated multi-centre case-control study","volume":"67","author":"Rozman","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/40.10.1157","article-title":"Anti-fibrillarin antibodies in systemic sclerosis","volume":"40","author":"Tormey","year":"2001","journal-title":"Rheumatology"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/art.24409","article-title":"Anti-U3 RNP autoantibodies in systemic sclerosis","volume":"60","author":"Aggarwal","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Svegliati Baroni","year":"2006","journal-title":"New Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/art.24365","article-title":"Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor \u03b1 in a subset of normal and systemic sclerosis patient sera","volume":"60","author":"Loizos","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/art.27209","article-title":"Autoantibodies against the platelet-derived growth factor receptor in scleroderma: comment on the articles by classen et\u00a0al. and loizos et al","volume":"60","author":"Gabrielli","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/art.24381","article-title":"Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis","volume":"60","author":"Classen","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1999.00961.x","article-title":"Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis","volume":"117","author":"Ihn","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"B97","article-title":"Anti-SSA (Ro52\/Ro60) and SSB autoantibodies in patients with systemic sclerosis","volume-title":"ARTHRITIS & RHEUMATOLOGY","author":"Aye","year":"2017"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101198","article-title":"SIGLEC-1 in systemic Sclerosis: A useful biomarker for differential diagnosis","volume":"15","author":"H\u00f6ppner","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3336","article-title":"Identification of new autoantibody specificities directed at proteins involved in the transforming growth factor \u03b2 pathway in patients with systemic sclerosis","volume":"13","author":"Bussone","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa831","article-title":"Rare immunofluorescence patterns of autoantibodies on HEp-2 cells defined by ICAP identify different autoimmune diseases in the absence of associated specificities: A Spanish multicentre study","volume":"60","author":"Irure-Ventura","year":"2021","journal-title":"Rheumatol (Oxf)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/art.39755","article-title":"Brief report: Anti-eukaryotic initiation factor 2B autoantibodies are associated with interstitial lung disease in patients with systemic sclerosis","volume":"68","author":"Betteridge","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex458","article-title":"Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1\/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis","volume":"57","author":"Pauling","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"key":"B103","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/ar4503","article-title":"Angiotensin receptor type 1 and endothelin receptor type a on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients","volume":"16","author":"Gunther","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/976427","article-title":"Primary biliary cirrhosis associated with systemic Sclerosis: Diagnostic and clinical challenges","volume":"2011","author":"Rigamonti","year":"2011","journal-title":"Int J Rheumatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1191\/096120301682430212","article-title":"Morphologic capillary changes and manifestations of connective tissue diseases in patients with primary biliary cirrhosis","volume":"10","author":"Fonollosa","year":"2001","journal-title":"Lupus"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-87366-w","article-title":"Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases","volume":"11","author":"Alsaed","year":"2021","journal-title":"Sci Rep"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.03.005","article-title":"A comparison of a fluorescence enzyme immunoassay versus indirect immunofluorescence for initial screening of connective tissue diseases: Systematic literature review and meta-analysis of diagnostic test accuracy studies","volume":"32","author":"Orme","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08946-w","article-title":"Systemic sclerosis - specific Antibodies : Novel and classical biomarkers","volume":"123456789","author":"Cavazzana","year":"2022","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1045523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T12:14:50Z","timestamp":1672834490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1045523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":108,"alternative-id":["10.3389\/fimmu.2022.1045523"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1045523","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.09.29.22280527","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"1045523"}}